Clinical Trials Logo

Clinical Trial Summary

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).


Clinical Trial Description

There will be up to 75 participants randomized 1:1:1 to receive either high dosage Withania somnifera extract (1088 mg daily), medium dosage Withania somnifera extract (544 mg daily) or matching placebo. The study will consist of a Screening Period, Randomization visit, Baseline visit, and Follow-up visits. The treatment period will be 8 weeks and a final follow up call will occur at Week 9. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031351
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact Hajara Abdirahman
Phone +1 (416)480-6860
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date September 2021
Completion date September 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04948645 - To Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Completed NCT02405182 - MRI Biomarkers in ALS
Completed NCT00696332 - Talampanel for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT03865420 - Amyotrophic Lateral Sclerosis (ALS) Families Project
Recruiting NCT04054141 - rTMS in Treatment of Spasticity N/A
Recruiting NCT03272503 - A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04259255 - Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02525471 - A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) Phase 1
Recruiting NCT03268603 - Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04138095 - Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care N/A
Recruiting NCT03698149 - ECoG BMI for Motor and Speech Control N/A
Recruiting NCT03373981 - Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS N/A
Completed NCT04165850 - Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS Phase 2
Completed NCT02469896 - A Trial of Tocilizumab in ALS Subjects Phase 2
Completed NCT01495390 - A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers N/A
Active, not recruiting NCT04165824 - Safety Study of Oral Edaravone Administered in Subjects With ALS Phase 3
Active, not recruiting NCT02429492 - Spinal Interneuron Excitability in ALS N/A
Recruiting NCT04569084 - Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS Phase 3
Completed NCT03214224 - Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot) N/A